Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 4/2015

01.03.2015 | R&D Insight Report

Vonoprazan: First Global Approval

verfasst von: Karly P. Garnock-Jones

Erschienen in: Drugs | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Vonoprazan (Takecab®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication. Phase III development is underway for the prevention of recurrence of duodenal and gastric ulcer in patients receiving aspirin or NSAID therapy. Phase I development was conducted in the UK for gastro-oesophageal reflux; however, no further development has been reported. This article summarizes the milestones in the development of vonoprazan leading to this first approval for acid-related diseases.
Literatur
1.
2.
3.
Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412–20.CrossRefPubMedCentralPubMed
4.
5.
6.
7.
Otsuka Pharmaceutical, Takeda Pharmaceutical Company Limited. Otsuka and Takeda announce a co-promotion agreement in Japan of TAK-438 for the treatment of acid-related diseases in the gastrointestinal therapeutic area (media release). 2014. http://​www.​otsuka.​co.​jp. Accessed 27 Mar 2014.
8.
Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231–8.CrossRefPubMed
9.
10.
Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55(9):4446–56.CrossRefPubMed
11.
Mizokami Y, Ashida K, Soen S, et al. TAK-438 vs. lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial [abstract no. Tu1054]. Gastroenterology. 2014;146(5 Suppl. 1):S-739.
12.
Kawai T, Ashida K, Mizokami Y, et al. TAK-438 vs. lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial (abstract no. Tu1055). Gastroenterology. 2014;146(5 Suppl. 1):S-739.
13.
Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis (abstract no. Tu1059). Gastroenterology. 2014;146(5 Suppl. 1):S-741.
14.
Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis (abstract no. Tu1052). Gastroenterology. 2014;146(5 Suppl. 1):S-738.
15.
Chiba T, Sakurai Y, Nishimura A, et al. A phase 2, randomized, double-blind, parallel-group, multicenter, dose-ranging study to evaluate the efficacy and safety of a novel potassium-competitive acid blocker (P-CAB) TAK-438 in patients with erosive esophagitis (abstract no. Mo1053). Gastroenterology. 2013;144(5 Suppl. 1):S-564-5.
16.
Murakami K, Sakurai Y, Shiino M, et al. A newly developed potassium-competitive acid blocker, vonoprazan vs. Lansoprazole in first-line triple therapy with amoxicillin, and clarithromycin for H. pylori eradication—phase 3, double-blind study (abstract no. W2.2). Helicobacter. 2014;19(Suppl 1):79.
17.
Murakami K, Sakurai Y, Shiino M, et al. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy With TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori (abstract no. Tu1056). Gastroenterology. 2014;146(5 Suppl. 1):S-740.
Metadaten
Titel
Vonoprazan: First Global Approval
verfasst von
Karly P. Garnock-Jones
Publikationsdatum
01.03.2015
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 4/2015
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0368-z

Weitere Artikel der Ausgabe 4/2015

Drugs 4/2015 Zur Ausgabe

Adis Drug Evaluation

Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections

Leading Article

Preventive Analgesia and Novel Strategies for the Prevention of Chronic Post-Surgical Pain

Review Article

The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents

Review Article

Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature

Therapy in Practice

Identification and Management of Alcohol Withdrawal Syndrome

Adis Drug Evaluation

Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout